|Back of an elderly woman with neurofibromatosis type 1|
|Symptoms||Small lumps within the skin, scoliosis, hearing loss, vision loss|
|Usual onset||Birth to early adulthood|
|Types||Neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), schwannomatosis|
|Diagnostic method||Symptoms, genetic testing|
|Treatment||Surgery, radiation therapy|
|Prognosis||NF1: normal life expectancy|
NF2: shortened life expectancy
|Frequency||1 in 3,000 people (United States)|
Neurofibromatosis (NF) is a group of three conditions in which tumors grow in the nervous system. The three types are neurofibromatosis type I (NF1), neurofibromatosis type II (NF2), and schwannomatosis. In NF1 symptoms include light brown spots on the skin, freckles in the armpit and groin, small bumps within nerves, and scoliosis. In NF2 there may be hearing loss, cataracts at a young age, balance problems, flesh colored skin flaps, and muscle wasting. The tumors are generally non-cancerous.
The cause is a genetic mutation in certain genes. These can be inherited from a person's parents, or in about half of cases spontaneously occur during early development. The tumors involve supporting cells in the nervous system rather than the neurons. In NF1 the tumors are neurofibromas (tumors of the peripheral nerves), while in NF2 and schwannomatosis tumors of Schwann cells are more common. Diagnosis is typically based on the signs and symptoms and occasionally supported by genetic testing.
There is no known prevention or cure. Surgery may be done to remove tumors that are causing problems or have become cancerous. Radiation and chemotherapy may also be used if cancer occurs. A cochlear implant or auditory brainstem implant may help some who have hearing loss.
In the United States, about 1 in 3,500 people have NF1 and 1 in 25,000 have NF2. Males and females are affected equally frequently. In NF1, symptoms are often present at birth and otherwise develop before 10 years of age. While the condition typically worsens with time, most people with NF1 have a normal life expectancy. In NF2, symptoms may not become apparent until early adulthood. NF2 increases the risk of early death. Descriptions of the condition occur as far back as the 1st century.
Signs and symptoms
Neurofibromatosis (NF1) in early life may cause learning and behavior problems – about 60% of children who have NF1 have a mild form of difficulty in school. In terms of signs the individual might have are the following:
- Six or more light brown dermatological spots ("café au lait spots")
- At least two neurofibromas
- At least two growths on the eye's iris
- Abnormal growth of the spine (scoliosis)
Neurofibromatosis is an autosomal dominant disorder, which means only one copy of the affected gene is needed for the disorder to develop. If one parent has neurofibromatosis, his or her children have a 50% chance of developing the condition as well. The severity of the condition of the parent does not affect the child; the affected child may have mild NF1 even though inherited from a parent with a severe form of the disorder. The types of neurofibromatosis are:
- Neurofibromatosis type I, in which the nerve tissue grows tumors (neurofibromas) that may be benign, may cause serious damage by compressing nerves and other tissues.
- Neurofibromatosis type II, in which bilateral acoustic neuromas (tumors of the vestibulocochlear nerve or cranial nerve 8 (CN VIII) also known as schwannoma) develop, often leading to hearing loss.
- Schwannomatosis, in which painful schwannomas develop on spinal and peripheral nerves.
The pathophysiology of neurofibromatosis (type 1) consists of the NF1 gene protein. This protein is a tumor suppressor and therefore serves as a signal regulator of cell proliferation and differentiation. A dysfunction of neurofibromin can affect regulation, and cause uncontrolled cell proliferation. Schwann cells in neurofibromas have a mutation in the NF1 alleles.
Conditions which may be confused with NF include:
Surgical removal of tumors is an option, however the risks involved should be assessed first. With regard to OPG (optic pathway gliomas), the preferred treatment is chemotherapy. However, radiotherapy isn't recommended in children who present with this disorder. It is recommended that children diagnosed with NF1 at an early age have an examination each year, which allows any potential growths or changes related to the disorder to be monitored.
In most cases, symptoms of NF1 are mild, and individuals live normal and productive lives. In some cases, however, NF1 can be severely debilitating and may cause cosmetic and psychological issues. The course of NF2 varies greatly among individuals. In some cases of NF2, the damage to nearby vital structures, such as other cranial nerves and the brain stem, can be life-threatening. Most individuals with schwannomatosis have significant pain. In some extreme cases the pain will be severe and disabling.
NF1 occurs in 1 in 3000 individuals and is equally prevalent among men and women. It is among the most common inherited nervous system disorders. Affected individuals have a 10- to 15-year reduction in life expectancy compared to the average person.
- "Neurofibromatosis Fact Sheet". NINDS. 3 February 2016. Archived from the original on 23 January 2018. Retrieved 16 April 2018. This article incorporates text from this source, which is in the public domain.
- "Learning about Neurofibromatosis". National Human Genome Research Institute (NHGRI). 16 August 2016. Archived from the original on 10 October 2016. Retrieved 7 November 2016. This article incorporates text from this source, which is in the public domain.
- Evans, Rosalie E. Ferner, Susan M. Huson, D. Gareth R. (2011). Neurofibromatoses in clinical practice. London: Springer. p. 1. ISBN 978-0-85729-628-3. Archived from the original on 10 September 2017. Retrieved 9 October 2015.
- "Neurofibromatosis". NHS Choices. NHS. Archived from the original on 25 September 2015. Retrieved 9 October 2015.
- "Neurofibromatosis". NINDS. NIH. Archived from the original on 4 October 2015. Retrieved 9 October 2015.
- "NINDS Neurofibromatosis Information Page". 23 February 2015. Archived from the original on 4 April 2015. Retrieved 21 April 2015.
- Choices, NHS. "Neurofibromatosis type 1 - Causes - NHS Choices". www.nhs.uk. Archived from the original on 24 September 2015. Retrieved 9 October 2015.
- "Neurofibromatosis type 1". Genetics Home Reference. 5 October 2015. Archived from the original on 10 September 2015. Retrieved 9 October 2015.
- "Neurofibromatosis type 2". Genetics Home Reference. 5 October 2015. Archived from the original on 10 September 2015. Retrieved 9 October 2015.
- Perry, Arie; Brat, Daniel J. (1 January 2010). Practical Surgical Neuropathology: A Diagnostic Approach. Elsevier Health Sciences. p. 435. ISBN 978-0443069826. Archived from the original on 2 May 2016.
- "Orphanet: Neurofibromatosis type 1". www.orpha.net. Archived from the original on 6 October 2015. Retrieved 13 October 2015.
- Boyd, Kevin P.; Korf, Bruce R.; Theos, Amy (July 2009). "Neurofibromatosis type 1". Journal of the American Academy of Dermatology. 61 (1): 1–14. doi:10.1016/j.jaad.2008.12.051. PMC 2716546. PMID 19539839.
- Conrad Fischer; Farshad Bagheri; Rajpal Manchandani; Richard Pinsker; Sudheer Chauhan; Parenkumar Patel; Mohammad Maruf; Dhaval Satani; Kaushik Doshi; Ayaz Alwani; Naveen Pathak; Craigh Thurm; Mohammad Babury; Mahendra C. Patel; Arthur Shalanov; Samir Sarkar; Sabiha Raouf; Jebun Nahar; Prakashkumar Patel (2010). Master the Board USMLE Step 2 CK. KAPLAN Medical. p. 287. ISBN 978-1-60714-653-7.
- "Neurofibromatosis. What is neurofibromatosis? Type 1 (NF1) | Patient". Patient. Archived from the original on 4 October 2015. Retrieved 9 October 2015.
- Friedman, J. M. (2014). Pagon, Roberta A.; Adam, Margaret P.; Ardinger, Holly H.; Wallace, Stephanie E.; Amemiya, Anne; Bean, Lora JH; Bird, Thomas D.; Dolan, Cynthia R.; Fong, Chin-To (eds.). Neurofibromatosis 1. Seattle (WA): University of Washington, Seattle. PMID 20301288. Archived from the original on 18 January 2017.
- Stevenson, David; Viskochil, David; Mao, Rong (2015). Pagon, Roberta A.; Adam, Margaret P.; Ardinger, Holly H.; Wallace, Stephanie E.; Amemiya, Anne; Bean, Lora JH; Bird, Thomas D.; Dolan, Cynthia R.; Fong, Chin-To (eds.). Legius Syndrome. Seattle (WA): University of Washington, Seattle. PMID 20945555. Archived from the original on 10 September 2017.
- El-Sobky, Tamer Ahmed; Elsayed, Solaf M.; El Mikkawy, Dalia M.E. (2015). "Orthopaedic manifestations of Proteus syndrome in a child with literature update". Bone Reports. 3: 104–108. doi:10.1016/j.bonr.2015.09.004. PMC 5365241. PMID 28377973.
- Choices, NHS. "Neurofibromatosis type 2 - Treatment - NHS Choices". www.nhs.uk. Archived from the original on 22 December 2015. Retrieved 11 October 2015.
- "Complex Neufibrmatosis type 1" (PDF). NHS.uk. NHS. Archived (PDF) from the original on 23 December 2015. Retrieved 13 October 2015.
- Choices, NHS. "Neurofibromatosis type 1 - Treatment - NHS Choices". www.nhs.uk. Archived from the original on 26 September 2015. Retrieved 11 October 2015.
- Norden, Andrew D.; Reardon, David A.; Wen, Patrick Y. (16 December 2010). Primary Central Nervous System Tumors: Pathogenesis and Therapy. Springer Science & Business Media. p. 459. ISBN 9781607611660. Archived from the original on 10 June 2016.
- Runge, Marschall S.; Patterson, Cam (18 November 2007). Principles of Molecular Medicine. Springer Science & Business Media. p. 1160. ISBN 9781592599639. Archived from the original on 9 May 2016.
- Upadhyaya, Meena; Cooper, David (29 January 2013). Neurofibromatosis Type 1: Molecular and Cellular Biology. Springer Science & Business Media. ISBN 9783642328640.
|Wikinews has related news: Interview with Reggie Bibbs on his life with neurofibromatosis|